Analystreport

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Evercore ISI. They now have a $395.00 price target on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com